Global Continence

Global Continence was founded with the mission to innovate solutions for bedwetting through advanced neuromodulation technology. The company's core vision is to provide effective, non-invasive treatments for individuals of all ages suffering from bedwetting. Their flagship product, Soluu®, employs transcutaneous nerve stimulation to intercept and curtail bedwetting episodes. Initially targeting children, Global Continence aims to expand its market focus to include adult and geriatric care, addressing a broad spectrum of needs within the continence care market.

Notable affiliated individuals and investors have not been disclosed publicly. However, the company has achieved significant milestones, including the development of Soluu®, which is currently under evaluation by the U.S. Food and Drug Administration (FDA). This pending approval highlights the potential impact of their technology on improving quality of life for those affected by bedwetting. Global Continence's innovative approach positions it as a promising player in the medical device industry, with the potential to make substantial contributions to continence care.